Portage Biotech Non Currrent Assets Other Over Time
| PRTG Stock | USD 4.62 0.10 2.21% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Portage Biotech Performance and Portage Biotech Correlation. Portage |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Portage Biotech. If investors know Portage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Portage Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 24.4 | Return On Assets (0.19) | Return On Equity (1.91) |
The market value of Portage Biotech is measured differently than its book value, which is the value of Portage that is recorded on the company's balance sheet. Investors also form their own opinion of Portage Biotech's value that differs from its market value or its book value, called intrinsic value, which is Portage Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Portage Biotech's market value can be influenced by many factors that don't directly affect Portage Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Portage Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Portage Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Portage Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Non Currrent Assets Other Analysis
Compare Portage Biotech and related stocks such as Amylyx Pharmaceuticals, Karuna Therapeutics, and Blueprint Medicines Corp Non Currrent Assets Other Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BPMC | 283 K | 283 K | 283 K | 283 K | 169 K | 1.8 M | 2.1 M | 5.9 M | 10.7 M | 15.4 M | 11.1 M | 19.8 M | 26.8 M | 30.6 M | 32.2 M |
| ARVN | 20.8 K | 20.8 K | 20.8 K | 20.8 K | 20.8 K | 20.8 K | 20.8 K | 20.8 K | 20.8 K | (1.3 M) | (2.4 M) | 7.5 M | 10.8 M | 10.4 M | 10.9 M |
| AVTE | 302 K | 302 K | 302 K | 302 K | 302 K | 302 K | 302 K | 302 K | 302 K | 302 K | 302 K | 302 K | 2.6 M | 2.3 M | 1.9 M |
| ANEB | 565.1 K | 565.1 K | 565.1 K | 565.1 K | 565.1 K | 565.1 K | 565.1 K | 565.1 K | 565.1 K | 565.1 K | 565.1 K | 565.1 K | 565.1 K | 508.6 K | 452.1 K |
| CUE | 98.5 K | 98.5 K | 98.5 K | 98.5 K | 98.5 K | 98.5 K | 117 K | 23.3 K | 2 M | 3.4 M | 3 M | 2.9 M | 3.2 M | 2.8 M | 2.1 M |
| KROS | 501 K | 501 K | 501 K | 501 K | 501 K | 501 K | 501 K | 501 K | 501 K | 115 K | 115 K | 82 K | 2.1 M | 2.1 M | 2.2 M |
| JANX | (21 K) | (21 K) | (21 K) | (21 K) | (21 K) | (21 K) | (21 K) | (21 K) | (21 K) | (21 K) | (155 K) | 392 K | 1.4 M | 3.3 M | 3.5 M |
| FENC | (1.0) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 262 K | 27 K | 27 K | 211 K | 6 K | 5.7 K |
| EWTX | 975 K | 975 K | 975 K | 975 K | 975 K | 975 K | 975 K | 975 K | 975 K | 975 K | 975 K | 3.5 M | 5.3 M | 348 K | 330.6 K |
| HRMY | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 1.7 M | 902 K | 4.3 M | 3.5 M | 6.6 M | 3.3 M |
| LCTX | (100 K) | 907 K | 733.8 K | 574 K | 790.1 K | 1.3 M | 1 M | 1 M | 505 K | 864 K | 616 K | 630 K | 627 K | 577 K | 556.9 K |
| MAIA | 654.7 K | 654.7 K | 654.7 K | 654.7 K | 654.7 K | 654.7 K | 654.7 K | 654.7 K | 654.7 K | 654.7 K | 654.7 K | 654.7 K | 214 K | 2.8 K | 2.7 K |
| ARMP | 300 K | (10 K) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.5 M | 836 K | (2.1 M) | (8.3 M) | (9.6 M) | 8.2 M | 8.6 M |
| DAWN | 107 K | 107 K | 107 K | 107 K | 107 K | 107 K | 107 K | 107 K | 107 K | 107 K | 107 K | 169 K | 469 K | 214 K | 263.7 K |
| ABOS | 144 K | 144 K | 144 K | 144 K | 144 K | 144 K | 144 K | 144 K | 144 K | 144 K | 14 K | 14 K | 151 K | 454 K | 476.7 K |
| XFOR | 363 K | 363 K | 363 K | 363 K | 363 K | 363 K | 1.4 M | 1.3 M | 639 K | 1.9 M | 3.3 M | 1.7 M | 1.2 M | 1.4 M | 1.6 M |
| INZY | 34 K | 34 K | 34 K | 34 K | 34 K | 34 K | 34 K | 34 K | 34 K | 56 K | 3.5 M | 3.4 M | 3.8 M | 2 M | 2.4 M |
Portage Biotech and related stocks such as Amylyx Pharmaceuticals, Karuna Therapeutics, and Blueprint Medicines Corp Non Currrent Assets Other description
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.My Equities
My Current Equities and Potential Positions
| Portage Biotech | PRTG |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Ontario; Canada |
| Exchange | NASDAQ Exchange |
USD 4.62
Check out Portage Biotech Performance and Portage Biotech Correlation. For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Portage Biotech technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.